Dedicated to Conquering Heart Failure

A clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease

COVID-19 and CVD

Cardiol received clearance from the FDA for its IND application to commence a Phase II/III clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history, or risk factors for, cardiovascular disease (CVD).

Learn More

Acute Myocarditis

Cardiol received clearance from the FDA for its IND application for a Phase II international trial CardiolRx™ in acute myocarditis, which remains a leading cause of sudden cardiac death in people under 35 years of age.

Learn More

Heart Failure

Committed to conquering a serious condition that affects more than 26 million people globally.

Learn More


All News


In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the Chairman of Cardiol Therapeutics, discusses the potential use for cannabidiol (CBD) in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.

In this discussion, Dr. Torre-Amione explains the potential benefits for anti-inflammatory therapies for these patients, as well as how CBD specifically can be applied. He also describes a use for CBD in treating cardiovascular disease related to viral damage, and what other anti-inflammatory therapies may soon be available.